Onkure Therapeutics Inc
OKUR3.010USD
-0.100-3.22%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
40.78MMarket Cap
0.09P/E TTM
More Details of Onkure Therapeutics Inc Company
OnKure Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a pipeline of tumor-agnostic candidates. It is developing OKI-219, a selective PI3KaH1047R inhibitor, as its lead program. It is engaged in targeting oncogenic PI3Ka and has multiple programs designed to enable targeting of this key oncogene. It is focused on delivering highly selective drug candidates that preserve wild-type PI3Ka while targeting the PI3Ka-mutated cancers, initially in advanced breast cancer. Its lead product candidate, OKI-219, is advancing in a phase I clinical trial. It also focuses on a development candidate targeting the most common PI3Ka mutations, such as H1047R, E545K, and E542K. Additionally, it is developing an allosteric inhibitor molecule.
Onkure Therapeutics Inc Info
Ticker SymbolOKUR
Company nameOnkure Therapeutics Inc
IPO dateApr 09, 2021
CEOSaccomano (Nicholas A)
Number of employees46
Security typeOrdinary Share
Fiscal year-endApr 09
Address6707 Winchester Circle, Suite 400
CityBOULDER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code80301
Phone17203072892
Websitehttps://onkuretherapeutics.com/
Ticker SymbolOKUR
IPO dateApr 09, 2021
CEOSaccomano (Nicholas A)
Company Executives of Onkure Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
15.32K
+56.70%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Dylan Hartley, Ph.D.
Dr. Dylan Hartley, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ed T. Mathers ,
Ed T. Mathers ,
Independent Director
Independent Director
--
--
Ms. Valerie M. Jansen, M.D., Ph.D.
Ms. Valerie M. Jansen, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. R. Michael Carruthers
Mr. R. Michael Carruthers
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Isaac Manke, Ph.D.
Dr. Isaac Manke, Ph.D.
Independent Director
Independent Director
15.32K
+56.70%
Mr. Michael (Mike) Grey
Mr. Michael (Mike) Grey
Executive Director
Executive Director
--
--
Mr. Jason A. Leverone, CPA
Mr. Jason A. Leverone, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nicholas A. Saccomano, Ph.D.
Dr. Nicholas A. Saccomano, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Samuel Agresta, M.D.
Dr. Samuel Agresta, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Andrew Philips, Ph.D.
Dr. Andrew Philips, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Acorn Capital Advisors, LLC
22.08%
Citadel Advisors LLC
7.90%
Shay Capital LLC
7.14%
Prosight Capital
5.80%
The Vanguard Group, Inc.
5.27%
Other
51.81%
Shareholders
Shareholders
Proportion
Acorn Capital Advisors, LLC
22.08%
Citadel Advisors LLC
7.90%
Shay Capital LLC
7.14%
Prosight Capital
5.80%
The Vanguard Group, Inc.
5.27%
Other
51.81%
Shareholder Types
Shareholders
Proportion
Investment Advisor
32.52%
Hedge Fund
25.67%
Investment Advisor/Hedge Fund
15.20%
Venture Capital
8.92%
Private Equity
3.82%
Individual Investor
1.73%
Research Firm
0.25%
Other
11.89%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
177
11.19M
86.97%
-5.51M
2025Q2
186
12.83M
100.04%
-1.08M
2025Q1
187
12.71M
99.28%
-1.05M
2024Q4
190
12.64M
105.50%
+4.22M
2024Q3
172
2.79M
546.32%
-1.40M
2024Q2
171
3.11M
93.03%
-1.12M
2024Q1
161
3.05M
91.28%
-864.58K
2023Q4
152
2.81M
85.98%
-309.72K
2023Q3
128
3.01M
91.00%
-83.83K
2023Q2
119
2.90M
88.58%
+621.98K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Acorn Capital Advisors, LLC
2.84M
22.11%
--
--
Jun 30, 2025
Citadel Advisors LLC
1.09M
8.48%
+21.21K
+1.99%
Jun 30, 2025
Shay Capital LLC
782.05K
6.09%
-28.17K
-3.48%
Jun 30, 2025
Prosight Capital
159.69K
1.24%
-26.88K
-14.41%
Jun 30, 2025
The Vanguard Group, Inc.
706.73K
5.5%
--
--
Jun 30, 2025
Highbridge Capital Management, LLC
663.61K
5.17%
+224.81K
+51.23%
Jun 30, 2025
Vestal Point Capital, LP
635.00K
4.94%
--
--
Jun 30, 2025
StepStone Group LP
491.94K
3.83%
--
--
Jun 30, 2025
Cantor Fitzgerald, L.P
669.54K
5.21%
+538.84K
+412.27%
Jun 30, 2025
New Enterprise Associates (NEA)
478.55K
3.73%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
ALPS Medical Breakthroughs ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 Covered Call ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
Proshares Ultra Russell 2000
0%
Global X Russell 2000 ETF
0%
View more
iShares Micro-Cap ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
ALPS Medical Breakthroughs ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Date
Type
Ratio
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
Oct 03, 2024
Merger
10→1
FAQs
Who are the top five shareholders of Onkure Therapeutics Inc?
The top five shareholders of Onkure Therapeutics Inc are:
Acorn Capital Advisors, LLC holds 2.84M shares, accounting for 22.11% of the total shares.
Citadel Advisors LLC holds 1.09M shares, accounting for 8.48% of the total shares.
Shay Capital LLC holds 782.05K shares, accounting for 6.09% of the total shares.
Prosight Capital holds 159.69K shares, accounting for 1.24% of the total shares.
The Vanguard Group, Inc. holds 706.73K shares, accounting for 5.50% of the total shares.
Acorn Capital Advisors, LLC holds 2.84M shares, accounting for 22.11% of the total shares.
Citadel Advisors LLC holds 1.09M shares, accounting for 8.48% of the total shares.
Shay Capital LLC holds 782.05K shares, accounting for 6.09% of the total shares.
Prosight Capital holds 159.69K shares, accounting for 1.24% of the total shares.
The Vanguard Group, Inc. holds 706.73K shares, accounting for 5.50% of the total shares.
What are the top three shareholder types of Onkure Therapeutics Inc?
The top three shareholder types of Onkure Therapeutics Inc are:
Acorn Capital Advisors, LLC
Citadel Advisors LLC
Shay Capital LLC
Acorn Capital Advisors, LLC
Citadel Advisors LLC
Shay Capital LLC
How many institutions hold shares of Onkure Therapeutics Inc (OKUR)?
As of 2025Q3, 177 institutions hold shares of Onkure Therapeutics Inc, with a combined market value of approximately 11.19M, accounting for 86.97% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -13.07%.
What is the biggest source of revenue for Onkure Therapeutics Inc?
In --, the -- business generated the highest revenue for Onkure Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
